Data / Form D filings / Pairidex Inc.
Pairidex Inc.: Form D filing
Pairidex Inc., a biotechnology company in St. Louis, MO, filed a Form D with the SEC in 2025. The latest, on February 20, 2025, reports $1.1 million sold of a $1.1 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 4340 DUNCAN AVE., SUITE 213, St. Louis, MO, 63110
- Phone
- (301) 580-8895
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2056818
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | New notice | $1,090,000 | $1,090,000 | 16 | May 15, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Todd Druley | Director | |
| Crystal Winkeler | Director | |
| Allyson Mayer | Executive Officer | |
| Andrew Young | Executive Officer, Director |
Every Form D from the week of Feb 17, 2025 · All recent filings in Missouri · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Pairidex Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.